Epidemiology

You have full text access to this OnlineOpen article

Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: Findings from a large, population-based, case–control study (the ProtecT study)

  1. Ali S. Murad1,
  2. Liz Down1,
  3. George Davey Smith1,2,
  4. Jenny L. Donovan1,
  5. Janet Athene Lane1,
  6. Freddie C. Hamdy3,
  7. David E. Neal4,
  8. Richard M. Martin1,2,†,*

Article first published online: 20 MAY 2010

DOI: 10.1002/ijc.25465

Issue

International Journal of Cancer

International Journal of Cancer

Volume 128, Issue 6, pages 1442–1448, 15 March 2011

Additional Information

How to Cite

Murad, A. S., Down, L., Davey Smith, G., Donovan, J. L., Athene Lane, J., Hamdy, F. C., Neal, D. E. and Martin, R. M. (2011), Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: Findings from a large, population-based, case–control study (the ProtecT study). Int. J. Cancer, 128: 1442–1448. doi: 10.1002/ijc.25465

Author Information

  1. 1

    Department of Social Medicine, University of Bristol, Bristol, United Kingdom

  2. 2

    MRC Centre for Causal Analyses in Translational Epidemiology, Department of Social Medicine, University of Bristol, Bristol, United Kingdom

  3. 3

    Nuffield Department of Surgery, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom

  4. 4

    Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, United Kingdom

  1. †

    Tel: +44(0)117 928 7321

*Department of Social Medicine, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS, United Kingdom

Publication History

  1. Issue published online: 20 MAY 2010
  2. Article first published online: 20 MAY 2010
  3. Accepted manuscript online: 20 MAY 2010 12:00AM EST
  4. Manuscript Accepted: 29 APR 2010
  5. Manuscript Received: 17 FEB 2010

Funded by

  • UK National Institute for Health Research Health Technology Assessment Programme. Grant Numbers: 96/20/06, 96/20/99
  • ProMPT (Prostate Mechanisms of Progression and Treatment)
  • NIHR Comprehensive Biomedical Research Centre Grant

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (147K)

References

  • 1
    Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin 2005; 55: 74–108.
    Direct Link:
  • 2
    De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7: 256–69.
  • 3
    Hussain T, Gupta S, Mukhtar H. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 2003; 191: 125–35.
  • 4
    Y Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Chargui J, Yoshimura N, Hla T, Wada S. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 2000; 89: 589–96.
    Direct Link:
  • 5
    Kirschenbaum A, Klausner AP, Lee R, Unger P, Yao S, Liu XH, Levine AC. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology 2000; 56: 671–6.
  • 6
    Uotila P, Valve E, Martikainen P, Nevalainen M, Nurmi M, Harkonen P. Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol Res 2001; 29: 25–8.
  • 7
    Zheng SL, Liu W, Wiklund F, Dimitrov L, Balter K, Sun J, Adami HO, Johansson JE, Sun J, Chang B. A comprehensive association study for genes in inflammation pathway provides support for their roles in prostate cancer risk in the CAPS study. Prostate 2006; 66: 1556–64.
    Direct Link:
  • 8
    Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 2005; 294: 914–23.
  • 9
    Rostom A, Dube C, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the US Preventive Services Task Force. Ann Intern Med 2007; 146: 376.
  • 10
    Langman MJS, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. Br Med J 2000; 320: 1642–6.
  • 11
    Corley D, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003; 124: 47–56.
  • 12
    Wang WH, Huang JQ, Zheng GF, Lam SK, Karlberg J, Wong BC. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2003; 95: 1784–91.
  • 13
    Khuder SA, Mutgi AB. Breast cancer and NSAID use: a meta-analysis. Br J Cancer 2001; 84: 1188–92.
  • 14
    Habel LA, Zhao W, Stanford JL. Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes Control 2002; 13: 427–34.
  • 15
    Perron L, Bairati I, Moore L, Meyer F. Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. Int J Cancer 2003; 106: 409–15.
    Direct Link:
  • 16
    Garcia Rodriguez LA, Gonzalez-Perez A. Inverse association between nonsteroidal anti-inflammatory drugs and prostate cancer. Cancer Epidemiol Biomarkers Prev 2004; 13: 649–53.
  • 17
    Jacobs EJ, Rodriguez C, Mondul AM, Connell CJ, Henley SJ, Calle EE, Thun MJ. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst 2005; 97: 975–80.
  • 18
    Dasgupta K, Di Cesar D, Ghosn J, Rajan R, Mahmud S, Rahme E. Association between nonsteroidal anti-inflammatory drugs and prostate cancer occurrence. Cancer J 2006; 12: 130–5.
  • 19
    Figueiredo JC, Grau MV, Haile RW, Sandler RS, Summers RW, Bresalier RS, Burke CA, McKeown-Eyssen GE, Baron JA. Folic acid and risk of prostate cancer: results from a randomized clinical trial. J Natl Cancer Inst 2009; 101: 432–5.
  • 20
    Menezes RJ, Swede H, Niles R, Moysich KB. Regular use of aspirin and prostate cancer risk (United States). Cancer Causes Control 2006; 17: 251–6.
  • 21
    Leitzmann MF, Stampfer MJ, Ma J, Chan JM, Colditz GA, Willett WC, Giovannucci E. Aspirin use in relation to risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2002; 11: 1108–11.
  • 22
    Paganini-Hill A, Chao A, Ross RK, Henderson BE. Aspirin use and chronic diseases: a cohort study of the elderly. Br Med J 1989; 299: 1247–50.
  • 23
    Norrish AE, Jackson RT, McRae CU. Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer 1998; 77: 511–5.
    Direct Link:
  • 24
    Neugut AI. Association between coronary heart disease and cancers of the breast, prostate, and colon. Cancer Epidemiol Biomarkers Prev 1998; 7: 869–73.
  • 25
    Platz EA, Rohrmann S, Pearson JD, Corrada MM, Watson DJ, De Marzo AM, Landis PK, Metter EJ, Carter HB. Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol Biomarkers Prev 2005; 14: 390–6.
  • 26
    Sorensen HT, Friis S, Norgard B, Mellemkjaer L, Blot WJ, McLaughlin JK, Ekbom A, Baron JA. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 2003; 88: 1687–92.
  • 27
    Murtola TJ, Tammela TLJ, Auvinen A. Non-steroidal anti-inflammatory drugs and prostate cancer risk—a population-based case-control study. Eur Urol Suppl 2008; 7: 198.
  • 28
    Roberts RO, Jacobson DJ, Girman CJ, Rhodes T, Lieber MM, Jacobsen SJ. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 2002; 77: 219–25.
  • 29
    Mahmud SM, Franco EL, Aprikian AG. Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int J Cancer 2010;doi:10.1002/ijc.25186.
    Direct Link:
  • 30
    Schwab JM, Schluesener HJ, Laufer S. COX-3: just another COX or the solitary elusive target of paracetamol? Lancet 2003; 361: 981–2.
  • 31
    Avery KNL, Blazeby JM, Lane JA, Neal DE, Hamdy FC, Donovan JL. Decision-making about PSA testing and prostate biopsies: a qualitative study embedded in a primary care randomised trial. Eur Urol 2008; 53: 1186–93.
  • 32
    Donovan J, Hamdy F, Neal D, Peters T, Oliver S, Brindle L, Jewell D, Powell P, Gillatt D, Dedman D. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess 2003; 7: 1–88.
  • 33
    Zuccolo L, Harris R, Gunnell D, Oliver S, Lane JA, Davis M, Donovan J, Neal D, Hamdy F, Beynon R, Savovic J, Martin RM. Height and prostate cancer risk: a large nested case-control study (ProtecT) and meta-analysis. Cancer Epidemiol Biomarkers Prev 2008; 17: 2325–36.
  • 34
    Giovannucci E, Rimm EB, Liu Y, Leitzmann M, Wu K, Stampfer MJ, Willett WC. Body mass index and risk of prostate cancer in US health professionals. J Natl Cancer Inst 2003; 95: 1240–4.
  • 35
    Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 2056–62.
  • 36
    Reijman M, Pols HAP, Bergink AP, Hazes JMW, Belo JN, Lievense AM, Bierma-Zeinstra SMA. Body mass index associated with onset and progression of osteoarthritis of the knee but not of the hip: the Rotterdam Study. Ann Rheum Dis 2007; 66: 158–62.
  • 37
    Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979; 241: 2035–2038.
  • 38
    Harlan LC, Potosky A, Gilliland FD, Hoffman R, Albertsen PC, Hamilton AS, Eley JW, Stanford JL, Stephenson RA. Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst 2001; 93: 1864–71.
  • 39
    Stenman UH, Finne P, Zhang WM, Leinonen J. Prostate-specific antigen and other prostate cancer markers. Urology 2000; 56: 893–8.
  • 40
    Singer EA, Palapattu GS, van Wijngaarden E. Prostate-specific antigen levels in relation to consumption of nonsteroidal anti-inflammatory drugs and acetaminophen. Cancer 2008; 113: 2053–7.
    Direct Link:
  • 41
    Fowke JH, Motley SS, Smith JA, Cookson MS, Concepcion R, Chang SS, Byerly S. Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume. J Urol 2009; 181: 2064–70.
  • 42
    Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED. Prevalence of prostate cancer among men with a prostate- specific antigen level ≥4.0 ng per milliliter. N Engl J Med 2004; 350: 2239–46.
  • 43
    Friis S, Nielsen GL, Mellemkjaer L, McLaughlin JK, Thulstrup AM, Blot WJ, Lipworth L, Vilstrup H, Olsen JH. Cancer risk in persons receiving prescriptions for paracetamol: a Danish cohort study. Int J Cancer 2002; 97: 96–101.
    Direct Link:
  • 44
    Scholes D, Stergachis A, Penna PM, Normand EH, Hansten PD. Nonsteroidal antiinflammatory drug discontinuation in patients with osteoarthritis. J Rheumatol 1995; 22: 708–12.
  • 45
    Morant SV, McMahon AD, Cleland JGF, Davey PG, MacDonald TM. Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity. Br J Clin Pharmacol 2004; 57: 188–98.
    Direct Link:
  • 46
    Porteous T, Bond C, Hannaford P, Sinclair H. How and why are non-prescription analgesics used in Scotland? Fam Pract 2005; 22: 78–85.
  • 47
    Antonov KI, Isacson DG. Prescription and nonprescription analgesic use in Sweden. Ann Pharmacother 1998; 32: 485–94.
  • 48
    Etzioni R, Cha R, Feuer EJ, Davidov O. Asymptomatic incidence and duration of prostate cancer. Am J Epidemiol 1998; 148: 775–85.
  • 49
    Bryant RJ, Hamdy FC. Screening for prostate cancer: an update. Eur Urol 2008; 53: 37–44.
View Full Article (HTML) Get PDF (147K)